IL2 and neoplasm: Tumor-infiltrating lymphocyte immunotherapy (TIL) is an adoptive cell transfer variant where tumor-infiltrating lymphocytes extracted from a metastatic melanoma tumor are cultured with IL-2, which serves to activate T-cells.